We will bring about a step change in gene therapy development.
We have a strong current pipeline with two programmes in development and a powerful discovery engine for future programmes – FunSel, our in-vivo screening platform.
We are challenging the status quo and are developing therapies that have the potential to stop or significantly slow down chronic kidney diseases.
Our pipeline has therapies in development for kidney diseases with high unmet need, encompassing rare monogenic diseases, as well as much more prevalent common forms of kidney disease. They both rapidly lead to end-stage renal disease, with devastating consequences to patients.